Integrated Bioinformatics Investigation and Experimental Validation Reveals the Clinical and Biological Significance of Chromobox Family in Breast Cancer

Overview

Journal Sci Rep

Specialty Science

Date 2025 Feb 22

PMID 39987187

Authors

Xin Ge

Shu Lei

Panliang Wang

Wenkang Wang

Meng Deng

Guiling Niu

Peng Du

Wendong Wang

Affiliations

Soon will be listed here.

Abstract

Chromobox (CBX) proteins are essential components of the Polycomb group and play pivotal roles in tumor onset, progression, and metastasis. However, the prognostic significance and functions of CBXs in the advancement of breast cancer (BC) have not been sufficiently investigated. A comprehensive analysis of the expression and prognostic relevance of CBX1-8 in BC was conducted comprehensively using The Cancer Genome Atlas (TCGA) and multiple databases. High mRNA expression of CBX2, CBX3, and CBX5 in BC patients was significantly associated with reduced overall survival (OS). Results from univariate and multivariate Cox regression analysis revealed that the mRNA expression level of CBX2 in BC patients served as an independent prognostic factor. In Luminal A and Luminal B BC subtypes, high expression of CBX2 correlated with unfavorable prognosis. Subsequent Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses indicated a strong association between CBX2 and the cell cycle as well as DNA replication processes. CCK-8 and EdU assays demonstrated that silencing CBX2 inhibited the proliferation of T47D and MCF7 cell lines. Moreover, the cell cycle assay indicated that CBX2 silencing led to cell cycle arrest, accompanied by a significant decrease in the levels of CDK4 and CyclinD1. Elevated CBX2 expression significantly correlated with the infiltration of T cells, B cells, macrophages, and dendritic cells in BC. Our findings could provide new perspectives for identifying potential prognostic markers within the CBX family in BC. Targeting CBX2 may present a promising approach to address endocrine resistance in BC therapy.

References

Baldominos P, Barbera-Mourelle A, Barreiro O, Huang Y, Wight A, Cho J . Quiescent cancer cells resist T cell attack by forming an immunosuppressive niche. Cell. 2022; 185(10):1694-1708.e19. PMC: 11332067. DOI: 10.1016/j.cell.2022.03.033. View

Ponde N, Zardavas D, Piccart M . Progress in adjuvant systemic therapy for breast cancer. Nat Rev Clin Oncol. 2018; 16(1):27-44. DOI: 10.1038/s41571-018-0089-9. View

Li T, Fan J, Wang B, Traugh N, Chen Q, Liu J . TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. Cancer Res. 2017; 77(21):e108-e110. PMC: 6042652. DOI: 10.1158/0008-5472.CAN-17-0307. View

Xu X, Lai C, Luo J, Shi J, Guo K, Hu J . The predictive significance of chromobox family members in prostate cancer in humans. Cell Oncol (Dordr). 2024; 47(4):1315-1331. DOI: 10.1007/s13402-024-00929-7. View

Mao J, Tian Y, Wang C, Jiang K, Li R, Yao Y . CBX2 Regulates Proliferation and Apoptosis via the Phosphorylation of YAP in Hepatocellular Carcinoma. J Cancer. 2019; 10(12):2706-2719. PMC: 6584921. DOI: 10.7150/jca.31845. View

Hutter C, Zenklusen J . The Cancer Genome Atlas: Creating Lasting Value beyond Its Data. Cell. 2018; 173(2):283-285. DOI: 10.1016/j.cell.2018.03.042. View

Cai X, Lv Y, Pan J, Cao Z, Zhang J, Li Y . CBX8 Promotes Epithelial-mesenchymal Transition, Migration, and Invasion of Lung Cancer through Wnt/β-catenin Signaling Pathway. Curr Protein Pept Sci. 2024; 25(5):386-393. DOI: 10.2174/0113892037273375231204080906. View

Brubaker L, Backos D, Nguyen V, Reigan P, Yamamoto T, Woodruff E . Novel chromobox 2 inhibitory peptide decreases tumor progression. Expert Opin Ther Targets. 2023; 27(4-5):361-371. DOI: 10.1080/14728222.2023.2218614. View

Gil J, OLoghlen A . PRC1 complex diversity: where is it taking us?. Trends Cell Biol. 2014; 24(11):632-41. DOI: 10.1016/j.tcb.2014.06.005. View

10.

Gyorffy B . Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancer. Comput Struct Biotechnol J. 2021; 19:4101-4109. PMC: 8339292. DOI: 10.1016/j.csbj.2021.07.014. View

11.

Zhou H, Xiong Y, Liu Z, Hou S, Zhou T . Expression and prognostic significance of CBX2 in colorectal cancer: database mining for CBX family members in malignancies and vitro analyses. Cancer Cell Int. 2021; 21(1):402. PMC: 8317347. DOI: 10.1186/s12935-021-02106-4. View

12.

Hu C, Li X, Zeng T, Ye D, Li Y, Yan H . Significance of chromobox protein (CBX) expression in diffuse LBCL. Gene. 2021; 813:146092. DOI: 10.1016/j.gene.2021.146092. View

13.

Clermont P, Crea F, Chiang Y, Lin D, Zhang A, Wang J . Identification of the epigenetic reader CBX2 as a potential drug target in advanced prostate cancer. Clin Epigenetics. 2016; 8:16. PMC: 4751702. DOI: 10.1186/s13148-016-0182-9. View

14.

Wang W, Liu Z, Chen X, Lu Y, Wang B, Li F . Downregulation of Suppresses the Proliferation and Induces the Apoptosis of Gastric Cancer Cells Through the Hippo Signaling Pathway. DNA Cell Biol. 2021; 40(8):1076-1086. DOI: 10.1089/dna.2021.0370. View

15.

Iqbal M, Siddiqui S, Rehman A, Siddiqui F, Singh P, Kumar B . Multiomics integrative analysis reveals antagonistic roles of CBX2 and CBX7 in metabolic reprogramming of breast cancer. Mol Oncol. 2021; 15(5):1450-1465. PMC: 8096797. DOI: 10.1002/1878-0261.12894. View

16.

Li T, Tian L, Cao J, Liu M . Cancer-associated fibroblasts secret extracellular vesicles to support cell proliferation and epithelial-mesenchymal transition in laryngeal squamous cell carcinoma. Mol Cell Probes. 2023; 72:101934. DOI: 10.1016/j.mcp.2023.101934. View

17.

Herrera F, Ronet C, Ochoa de Olza M, Barras D, Crespo I, Andreatta M . Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy. Cancer Discov. 2021; 12(1):108-133. PMC: 9401506. DOI: 10.1158/2159-8290.CD-21-0003. View

18.

Colwill K, Graslund S . A roadmap to generate renewable protein binders to the human proteome. Nat Methods. 2011; 8(7):551-8. DOI: 10.1038/nmeth.1607. View

19.

Gao Z, Zhang J, Bonasio R, Strino F, Sawai A, Parisi F . PCGF homologs, CBX proteins, and RYBP define functionally distinct PRC1 family complexes. Mol Cell. 2012; 45(3):344-56. PMC: 3293217. DOI: 10.1016/j.molcel.2012.01.002. View

20.

Jiang N, Niu G, Pan Y, Pan W, Zhang M, Zhang C . CBX4 transcriptionally suppresses KLF6 via interaction with HDAC1 to exert oncogenic activities in clear cell renal cell carcinoma. EBioMedicine. 2020; 53:102692. PMC: 7044754. DOI: 10.1016/j.ebiom.2020.102692. View